Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-26-013242
Filing Date
2026-03-27
Accepted
2026-03-27 17:00:36
Documents
90
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K form10-k.htm   iXBRL 10-K 4218503
2 EX-21.1 ex21-1.htm EX-21.1 5635
3 EX-23.1 ex23-1.htm EX-23.1 3813
4 EX-23.2 ex23-2.htm EX-23.2 3816
5 EX-31.1 ex31-1.htm EX-31.1 18310
6 EX-31.2 ex31-2.htm EX-31.2 18422
7 EX-32.1 ex32-1.htm EX-32.1 7841
8 EX-32.2 ex32-2.htm EX-32.2 7747
  Complete submission text file 0001493152-26-013242.txt   15712796

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE cldi-20251231.xsd EX-101.SCH 96020
10 XBRL CALCULATION FILE cldi-20251231_cal.xml EX-101.CAL 114456
11 XBRL DEFINITION FILE cldi-20251231_def.xml EX-101.DEF 373468
12 XBRL LABEL FILE cldi-20251231_lab.xml EX-101.LAB 802558
13 XBRL PRESENTATION FILE cldi-20251231_pre.xml EX-101.PRE 578621
93 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 2878469
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40789 | Film No.: 26808340
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)